A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors
* Any other laboratory abnormality deemed clinically significant by the Sponsor or the Investigator.
You may not be if
Current or prior treatment for CHB with lamivudine, telbivudine, adefovir, HBV core inhibitor, or previous treatment with an investigational agent for HBV infection
Presence of substitutions in the HBV polymerase coding region which may confer reduced susceptibility to NrtIs
Co-infection with human immunodeficiency virus, hepatitis A virus, hepatitis C virus, hepatitis E virus, or hepatitis D virus
Females who are lactating or wish to become pregnant during the course of the trial
History or evidence of advanced liver disease or hepatic decompensation
Clinically significant cardiac disease including poorly-controlled or unstable hypertension; pulmonary disease; chronic or recurrent renal or urinary tract disease; liver disease other than CHB; endocrine disorder; autoimmune disorder; poorly controlled diabetes mellitus; neuromuscular, musculoskeletal, or mucocutaneous conditions requiring frequent treatment, seizure disorders requiring treatment; ongoing infection or other medical conditions requiring frequent medical management or pharmacologic or surgical treatment that, in the opinion of the Investigator or the Sponsor, makes the subject unsuitable for trial participation
History of hepatocellular carcinoma (HCC)
Exclusionary laboratory parameters at Screening:
* Platelet count \<100,000/mm\^3
* Albumin \<lower limit of normal
* Total bilirubin \>1.2 × upper limit of normal (ULN)
* Direct bilirubin \>1.2 × ULN
* ALT \>10 × ULN
Clareo Health | A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors
